Skip to content
Menu

Eikon Therapeutics Receives FDA Clearance To Proceed For Investigational New Drug Application To Evaluate EIK1006 For Treatment Of Advanced Metastatic Prostate Cancer; Expects Initial Clinical Data From Phase 1/2 Study In H2 2027

Benzinga Newsdesk 13 hours ago

FDANews

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

Eikon plans to initiate a Phase 1/2 study, ARGATE-001, to evaluate the safety, tolerability and preliminary efficacy of EIK1006 in participants with metastatic androgen-pathway-modulation-resistant prostate cancer (mAPMRPC) that has progressed on established anti-hormonal therapy. Formerly known as metastatic castration-resistant prostate cancer (mCRPC), mAPMRPC remains an area of high unmet need because resistance to established anti-hormonal therapy is common and limits durable benefit. EIK1006 is intended to address resistance driven by androgen receptor (AR) pathway alterations, including AR amplification and ligand-binding domain mutations. Eikon expects to begin dosing participants in this study in 2027, with preliminary safety and efficacy data to be available in the second half of 2027.

Read at benzinga.com